Pirtobrutinib demonstrates safety and progression-free survival benefits in patients with relapsed/refractory mantle cell lymphoma, suggesting its value after prior therapies.
Key Points
Pirtobrutinib achieved an overall response rate of 49.3% in patients with relapsed/refractory mantle cell lymphoma.
The median progression-free survival for patients pre-treated with cBTKi was 5.6 months, indicating limited durability.
Assessment included chemotherapy and adverse events in patients, ensuring a comprehensive safety profile.
Findings highlight the safety and efficacy of pirtobrutinib in heavily pre-treated patients with relapsed/refractory mantle cell lymphoma.